Negative HER-2 overexpression was found in 38% and 51% of the TOMO and IMRT groups, respectively (relative risk [RR], 0.63; 95% CI 0.40 –0.99; P = 0.053).With regard to the degree of tumor differentiation, poor- moderate differentiation was 69% in the TOMO group and 81% in the IMRT group (RR 0.53; 95% CI, 0.31 –0.89; P = 0.052). The gene discussed is ERBB2; the disease is neoplasm.